Evaluating Indocyanine Green Fluorescence ICG Use During Laparoscopic Heller-Dor Surgery for Achalasia Types I and II

What this Trial Is About

Achalasia is a rare disorder affecting the movement of the lower esophageal sphincter, classified into types I, II, and III. This study focuses on patients with types I and II achalasia undergoing laparoscopic Heller-Dor surgery, which is the standard treatment for these types. Researchers are evaluating the potential role of Indocyanine Green Fluorescence ICG during this surgery to better detect mucosal leaks and improve surgical outcomes. The study observes patients undergoing the laparoscopic Heller-Dor procedure with the use of ICG fluorescence as a tool during surgery. The investigators aim to determine if ICG can identify intraoperative mucosal leaks and guide myotomy adjustments. They also plan to assess the need for postoperative esophagogastric radiographic control and compare clinical features, perioperative outcomes, and follow-up results over 12 months between patients with and without ICG use. Participants will be monitored through clinical assessments, perioperative complication tracking, and length of hospital stay from the first to fourth postoperative day. The primary outcomes measured are intraoperative detection of mucosal leaks and completeness of the myotomy. Secondary outcomes include perioperative complications and postoperative recovery. Follow-up will extend to 12 months to evaluate longer-term results and the potential benefits of using ICG during surgery.

The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor